Parabilis Medicines, Inc. (PBLS)
NASDAQ: PBLS · Real-Time Price · USD
40.42
-0.33 (-0.81%)
At close: Sep 4, 2026, 4:00 PM EDT
39.31
-1.11 (-2.75%)
After-hours: Sep 4, 2026, 7:45 PM EDT
Parabilis Medicines Stock Forecast
Stock Price Forecast
According to 5 analysts polled by S&P Global, Parabilis Medicines stock has a consensus rating of "Strong Buy" and an average price target of $41.75. The average 1-year stock price forecast is 3.29% higher than the current stock price, while the lowest is $40 (-1.04%) and the highest is $45 (+11.33%).
Price Target: $41.75 (+3.29%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Parabilis Medicines stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Bank of America Securities | Bank of America Securities | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Aug 14, 2026 |
| Guggenheim | Guggenheim | Buy Maintains $40 | Buy | Maintains | $40 | -1.04% | Aug 14, 2026 |
| LifeSci Capital | LifeSci Capital | Buy Maintains $42 | Buy | Maintains | $42 | +3.91% | Aug 13, 2026 |
| Leerink Partners | Leerink Partners | Buy Initiates $40 | Buy | Initiates | $40 | -1.04% | Jul 6, 2026 |
| Evercore ISI | Evercore ISI | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Jul 6, 2026 |
Financial Forecast
Revenue This Year
1.03M
Revenue Next Year
3.33M
from 1.03M
Increased by 222.58%
EPS This Year
-2.58
EPS Next Year
-2.19
from -2.58
EPS and Forward PE are based on non-GAAP adjusted numbers.